An Open-Label Naturalistic Pilot Study of Acamprosate in Youth with Autistic Disorder
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
To date, placebo-controlled drug trials targeting the core social impairment of autistic disorder (autism) have had uniformly negative results. Given this, the search for new potentially novel agents targeting the core social impairment of autism continues. Acamprosate is U.S. Food and Drug Administration-approved drug to treat alcohol dependence. The drug likely impacts both gamma-aminobutyric acid and glutamate neurotransmission. This study describes our initial open-label experience with acamprosate targeting social impairment in youth with autism. In this naturalistic report, five of six youth (mean age, 9.5 years) were judged treatment responders to acamprosate (mean dose 1,110 mg/day) over 10 to 30 weeks (mean duration, 20 weeks) of treatment. Acamprosate was well tolerated with only mild gastrointestinal adverse effects noted in three (50%) subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025014929212 · Cited by 1,611 · cited 4×
“The secondary parent-rated outcome measure used was the social responsiveness scale (SRS) (Constantino et al. 2003).”
MethodInfluentialThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 4×
“Use of acamprosate in three adults with fragile X syndrome (FXS) and comorbid PDDs was recently described (Erickson et al. 2010).”
BackgroundInfluentialPostmortem brain abnormalities of the glutamate neurotransmitter system in autism
Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001) · Neurology · doi:10.1212/wnl.57.9.1618 · Cited by 518
Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01430-0 · Cited by 500
GABAA Receptor Downregulation in Brains of Subjects with Autism
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., & Thuras, P. D. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0646-7 · Cited by 439
Naltrexone in autistic children: Behavioral symptoms and attentional learning
CAMPBELL, M., ANDERSON, L. T., SMALL, A. M., ADAMS, P., GONZALEZ, N. M., & ERNST, M. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199311000-00024 · Cited by 210 · cited 2×
“2008), naltrexone (Campbell et al. 1993), lamotrigine (Belsito et al.”
BackgroundPlasma amino acid levels in children with autism and their families
Aldred, S., Moore, K. M., Fitzgerald, M., & Waring, R. H. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1022238706604 · Cited by 188 · cited 2×
“Peripheral glutamate has been shown to be increased in youth (Aldred et al. 2003) and adults (Shinohe et al. 2006) with autism compared with controls.”
BackgroundBlednov, Y. A., & Adron Harris, R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008584 · Cited by 123
Brief Report: Acamprosate in Fragile X Syndrome
Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67
Self-citation
Cited by
GABA system dysfunction in autism and related disorders: From synapse to symptoms
Coghlan, S., Horder, J., Inkster, B., Mendez, M. A., Murphy, D. G., & Nutt, D. J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.005 · Cited by 446
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L.-S., Long, S., Ke, X.-Y., Fukunaga, K., Lu, Y.-M., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 258
Frye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, J., Rosenfelt, C., Gertner, M. J., Campbell, S. R., Emerson, D., Hinchey, P., Kollaros, M., et al. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00136 · Cited by 46
Rais (2022) · doi:10.1101/2022.02.08.479618 · Cited by 2
Metadata
- Authors
- Erickson, C. A., Early, M., Stigler, K. A., Wink, L. K., Mullett, J. E., & McDougle, C. J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-12
- Volume
- 21
- Issue
- 6
- Pages
- 565-569
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2026866320
- Cited by
- 53
- References
- 9
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label Naturalistic Pilot Study of Acamprosate in Youth with Autistic Disorder. https://app.cochat.ai/papers/10.1089/cap.2011.0034
- The paper
- Erickson, C. A., Early, M., Stigler, K. A., Wink, L. K., Mullett, J. E., & McDougle, C. J. (2011). An Open-Label Naturalistic Pilot Study of Acamprosate in Youth with Autistic Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2011.0034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.